Fortrea Holdings Inc. · NASDAQ:FTRE

Fortrea — Investor Presentation (2024)

7 slides from Fortrea's investor presentation, Nov 22, 2024

  1. Slide 1: Understanding Fortrea Experience Metrics

    Understanding Fortrea Experience Metrics Any Questions Contact: Pedro Larco [email protected] Fortrea Primary TA Experience: Fortrea GCD-Only TA Experience: Detailed Therapeutic Area Slides: 5,926 (5,900+) studies 5,224 Studies, 115k+ sites, >1.08M+ subjects Includes data where study has TA li

  2. Slide 2: Experience Data: Ophthalmology 2019-2023

    Experience Data: Ophthalmology 2019-2023 ©2024 Fortrea Inc. All rights reserved. Fortrea.com

  3. Slide 3: Fortrea Experience Brought to Your Trial

    Fortrea Experience Brought to Your Trial Presence Across Development Continuum – Trials Running between January 2019 – December 2023 Clin Pharm + Phase I PHASE I-II PHASE II PHASE III PHASE IV MULTIPLE1 DEVICE2 TOTAL 544 1,723 Studies 1,723 196 744 894 461 1,364 544 5,926 1,364 5,926 Total Studies U

  4. Slide 4: Fortrea Global Commercial Development Experience by Therapeutic Area (2019-2023)

    Fortrea Global Commercial Development Experience Sorted by PRIMARY or SECONDARY Therapeutic Area (2019-2023) Therapeutic Area Number of Studies Number of Sites Number of Subjects Bone & Joint Disease 204 4,713 25,000 Cardiovascular 387 9,104 123,511 Dermatology 209 5,627 23,928 Endocrinology and Met

  5. Slide 5: Global Commercial Development Experience Brought to Your Trial

    5-YEAR SUMMARY BY PHASE: GCD Global Commercial Development Experience Brought to Your Trial Presence Across Development Continuum – Trials Running between January 2019 – December 2023 Phase I PHASE I-II PHASE II PHASE III PHASE IV MULTIPLE1 DEVICE2 TOTAL 544 1,051 Studies 1,051 196 744 894 461 1,364

  6. Slide 6: Global Commercial Development Experience – Ophthalmology

    5-YEAR SUMMARY Global Commercial Development Experience – Studies By Phase Ophthalmology Top Indications* Wet AMD 21.2% 12 12 Phase I 4 Glaucoma or Ocular Hypertension 13.6% Sites: Phase I-II 1,945 17 Phase II Neuromyelitis Optica Spectrum Disorder (NMOSD) 12.1% Patients: 113 18 Phase III Geographic

  7. Slide 7: Thank you

    Thank you ©2024 Fortrea Inc. All rights reserved. Fortrea.com

Fortrea Holdings — Investor Presentation (2024) on 6ix